MGM Resorts International (NYSE:MGM) said its Q3 net loss narrowed relative to last year, yet fell short of analysts' expectations and revenue slightly missed the consensus of analysts polled by Capital IQ. The casino operator reported a Q3 net loss, adjusted for non-recurring costs, of $0.02 per share, compared to an adjusted net loss of $0.08 per share in the year-ago period. Analysts were expecting profit of $0.06 per share.MGM Resorts International (NYSE:MGM) said its Q3 net loss decreased to $20.2 million, or $0.04 per share, from $22.3 million, or $0.05 per share. Revenues rose 0.9% year-on-year to $2.48 billion, slightly below the Street estimate of $2.49 billion. "While we expected to have some negative impact to margins during the quarter as a result of the disruptions related to our investments in Delano at Mandalay Bay and the Strip frontage at Monte Carlo, we were also negatively affected by lower year over year table games hold and an increase in certain expenses.," said Jim Murren, Chairman and Chief Executive Officer of MGM Resorts International.Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) reported Q3 earnings that were better than analysts expected, raised the lower end of the guidance range for FY14 EPS and narrowed its revenue guidance range to miss the Street's view. The pharmaceutical company said non-GAAP earnings rose 3% to $1.32 per diluted share, exceeding the $1.24 average estimate from analysts polled by Capital IQ. Revenue was nearly unchanged at to $5.06 billion compared to the $5.09 billion consensus estimate. Reported net income rose to $876 million or $1.02 per diluted share from $711 million or $0.84 a year ago.Meanwhile, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) said it is raising the lower end of its guidance range and now expects EPS between $5.00 and $5.10 compared to previously $4.90 to $5.10, exceeding the $4.92 consensus. Revenue is now seen between $20 billion and $20.3 billion compared to the previous range between $19.9 billion and $20.8 billion, falling short of the $20.4 billion consensus. The company also added $1.7 billion to its share buyback program, bringing the total to $3 billion.Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) a specialty biopharmaceutical company, reported Q3 results that beat consensus on both EPS and total revenues, with an increase in sales from the company's XIAFLEX product. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) reported adjusted EPS of $0.27, up from $0.18 in Q3 2013 and beating analyst estimates of $0.15. Total revenues of $109.6 million were up from $108.1 million in Q3 2013 and topped analyst projections of $101.0 million. Sales of the company's XIAFLEX, a drug used to treat Peyronie's disease and Dupuytren's contracture, showed the biggest gains with sales of $38.6 million, up from $17.6 million in Q3 2013. Shares of AUXL are at $31.81 within a 52-week range of $16.71 - $33.00.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
